Subject(s)
Leg Dermatoses/diagnosis , Lupus Erythematosus, Cutaneous/diagnosis , Biopsy , Facial Dermatoses/complications , Facial Dermatoses/diagnosis , Facial Dermatoses/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Leg Dermatoses/complications , Leg Dermatoses/drug therapy , Leg Dermatoses/pathology , Lupus Erythematosus, Cutaneous/complications , Lupus Erythematosus, Cutaneous/drug therapy , Lupus Erythematosus, Cutaneous/pathology , Middle Aged , Prednisolone/therapeutic use , Scalp Dermatoses/complications , Scalp Dermatoses/diagnosis , Scalp Dermatoses/drug therapy , Skin/pathology , Undifferentiated Connective Tissue Diseases/complicationsABSTRACT
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
Subject(s)
Disease Management , Evidence-Based Medicine/methods , Gout Suppressants/therapeutic use , Gout/drug therapy , HumansABSTRACT
With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in >30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.
